CD19 PE

CD19 PE
Regulatory status
CE IVD
Antigen
CD19
Format
PE
Reactivity
Human
Application
FC (QC tested)
Excitation laser
blue (488 nm)
Variant
100 tests
ED7017
In stock
220.00 USD
Variant
0.1 mg
11-261-C100
In stock
220.00 USD
Product details
Images
References
Application
FC (QC tested)
Reactivity
Human
Description
The reagent CD19 PE permits identification and enumeration of cell populations expressing human CD19 antigen in whole blood using flow cytometry.
Contents
The reagent contains mouse monoclonal antibody against human CD19 antigen (clone LT19) which was purified by affinity chromatography and labeled with R-Phycoerythrin (PE). The labeled antibody is diluted at optimum concentration in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide. The content of a vial (2 ml) is sufficient for 100 tests.
Preparation
The purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended for In Vitro Diagnostic Use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
ED7017_FC_Profil Značení
Flow cytometry surface staining pattern of human peripheral whole blood after erythrocyte lysis from a healthy donor stained using CD19 (LT19) PE antibody (20 μl reagent / 100 μl of peripheral whole blood).
ED7017_FC_Histogram
Histogram showing separation of human CD19 positive B cells (red-filled) from CD19 negative cells - neutrophil granulocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood after erythrocyte lysis from a healthy donor stained using CD19 (LT19) PE antibody (20 μl reagent / 100 μl of peripheral whole blood).

Product specific references:

Elias F et al. (2003) Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 171: 3697-704
Inabe K and Kurosaki T (2002) Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood 99: 584-589
Fujimoto M et al. (1999) CD19 amplifies B lymphocyte signal transduction by regulating Src-Family protein tyrosine kinase activation. J Immunol. 162: 7088-7094
Shi X et al. (2007) CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 56: 3057-3069
van Zelm MC et al. (2006) An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 354: 1901-1912
Lin CW et al. (2005) CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 106: 3567-74
Variant
100 tests
ED7017
In stock
220.00 USD
Variant
0.1 mg
11-261-C100
In stock
220.00 USD